We are monitoring the impact of COVID-19 & Recession alarm on APAC Parkinson’s Disease Treatment Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) – Industry Size, Share, Trends, Growth & Forecasts (2022 to 2027)

Published: January, 2022
ID: 7150
Pages: 145

APAC Parkinson’s Disease Treatment Market Size & Growth (2022 to 2027)

The size of the Asia Pacific Parkinson’s Disease Treatment Market was worth USD 1.04 billion in 2020 and estimated to be growing at a CAGR of 6.79%, to reach USD 1.44 billion by 2025.

The continually increasing number of aging people and increased prevalence of Parkinson's disease are the major factors that are boosting the demand of the Asia Pacific Parkinson's disease treatment market. The development of innovative and novel treatment methods and increasing popularity for minimally invasive surgeries among the people are propelling the growth of the Asia Pacific Parkinson's disease treatment market. The increasing awareness among the people regarding healthcare is also boosting up the growth rate of Parkinson's disease treatment market in the Asia Pacific. The availability of key market players and an increasing number of manufacturers are also contributing to the growth of the APAC Parkinson's disease treatment market.  

An increasing account of the geriatric population and continuously growing patient base are likely to boost the demand for Parkinson's treatments and expand growth opportunities for the stakeholders in the APAC market. Increasing focus on the R&D activities by the private and public organizations for developing novel and innovative treatment methods owing to immense advancements in healthcare are expected to be creating more growth opportunities for the market over the forecast period. Emerging economies of the developed and developing countries such as India, China, Japan and others in the Asia Pacific are expected to create lucrative opportunities for the market players in the region during the forecast period. Patent expiration of many prominent drugs is foreseen to create lucrative opportunities for the key players in the Asia Pacific Parkinson's disease treatment market.

Stringent regulatory rules and policies are the significant challenges to the growth rate of Parkinson's disease treatment market in this area. Unfavorable reimbursement policies are limiting the growth of Asia Pacific Parkinson's disease treatment market. The availability of alternative treatments is a major challenge for the growth of the Asia Pacific Parkinson's disease treatment market and is expected to restrain the market during the forecast period.

This research report on the Asia Pacific Parkinson’s Disease Treatment Market has been segmented and sub-segmented into the following categories:

By Drug Class: 

  • Dopamine Receptor Antagonists

    • Pramipexole

    • Ropinirole

    • Apomorphine

    • Rotigotine

  • Mono Amine Oxidase Inhibitors

    • Selegiline

    • Rasagiline

  • Carbidopa

  • Anticholinergics

  • Other Drug Classes

By Distribution Channels: 

  • Retailer Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies

By Patient Care Setting:

  • Clinics

  • Hospitals 

By Country:

  • India

  • China

  • Japan

  • South Korea

  • Australia

  • New Zealand

  • Thailand

  • Malaysia

  • Vietnam

  • Philippines

  • Indonesia

  • Singapore

  • Rest of APAC

Regionally, Asia Pacific region is expected to have the fastest growth rate during the forecast period, owing to the huge population base in the region.

Key market participants leading the APAC Parkinson’s Disease Treatment Market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Asia Pacific Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    Asia Pacific Dopamine Receptor Antagonists Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Mono Amine Oxidase Inhibitors Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Carbidopa Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Anticholinergics  Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Other Drug Classes Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    Asia Pacific Retailer Pharmacies Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Hospital Pharmacies  Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Online Pharmacies Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )
    Asia Pacific Clinics  Market By Region, From 2022 - 2027 ( USD Billion )
    Asia Pacific Hospitals Market By Region, From 2022 - 2027 ( USD Billion )
    Japan Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    Japan Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    Japan Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )
    China Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    China Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    China Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )
    India Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    India Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    India Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )
    Australia Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    Australia Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    Australia Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )
    South Korea Parkinson’s Disease Treatment Market By Drug Class , From 2022 - 2027 ( USD Billion )
    South Korea Parkinson’s Disease Treatment Market By Distribution Channel , From 2022 - 2027 ( USD Billion )
    South Korea Parkinson’s Disease Treatment Market By Patient Care Setting, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample